In the CNS tumors, the most common oncogenic alterations occurring in > 5% of the cases were BRAF rearrangements/mutations (21%), TP53 mutations/deletions (12%) and CDKN2A/B deletions (6%) (Supplementary Fig. 2). This evidence concerns the gene BRAF and central nervous system neoplasm.